Relief Therapeutics Holding (V6M) Stock Overview

A biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. More details

V6M fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings have declined by 17.8% per year over past 5 years

Does not have a meaningful market cap (€33M)

Volatile share price over the past 3 months compared to the German market

V6M Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Relief Therapeutics Holding SA Competitors

Price History & Performance

Summary of share price highs, lows and changes for Relief Therapeutics Holding
Historical stock prices
Current Share Price	CHF 2.92
52 Week High	CHF 3.87
52 Week Low	CHF 2.19
Beta	-0.33
1 Month Change	-0.34%
3 Month Change	1.39%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	22.74%

Recent updates

Shareholder Returns

	V6M	DE Biotechs	DE Market
7D	-7.5%	1.3%	-3.3%
1Y	n/a	-29.9%	10.6%

Return vs Industry: Insufficient data to determine how V6M performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how V6M performed against the German Market.

Price Volatility

Is V6M's price volatile compared to industry and market?
V6M volatility
V6M Average Weekly Movement	8.3%
Biotechs Industry Average Movement	8.5%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.9%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: V6M's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine V6M's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	28	n/a	www.relieftherapeutics.com

Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium phenylbutyrate for the treatment of urea cycle disorders; and PKU GOLIKE for the dietary management of phenylketonuria. It also develops RLF-100, a synthetic form of vasoactive intestinal peptide for the treatment of acute respiratory distress syndrome and certain chronic lung diseases, including sarcoidosis, berylliosis, and checkpoint inhibitor-induced pneumonitis.

Relief Therapeutics Holding SA Fundamentals Summary

How do Relief Therapeutics Holding's earnings and revenue compare to its market cap?
V6M fundamental statistics
Market cap	€35.33m
Earnings (TTM)	-€18.40m
Revenue (TTM)	€4.38m

8.1x

P/S Ratio

-1.9x

P/E Ratio

Is V6M overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
V6M income statement (TTM)
Revenue	CHF 4.05m
Cost of Revenue	CHF 1.61m
Gross Profit	CHF 2.44m
Other Expenses	CHF 19.48m
Earnings	-CHF 17.04m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Apr 02, 2026

Earnings per share (EPS)	-1.35
Gross Margin	60.24%
Net Profit Margin	-420.33%
Debt/Equity Ratio	0%

How did V6M perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/11/18 13:40
End of Day Share Price	2025/11/18 00:00
Earnings	2025/06/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Relief Therapeutics Holding SA is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Alexandre Müller	Research Dynamics
Bob Pooler	ValuationLAB AG

Relief Therapeutics Holding SADB:V6M Stock Report